FRIENDSWOOD, Texas –(BUSINESS THREAD)–Castle Biosciences, Inc. (Nasdaq: CSTL), a company that improves health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2022, after the close of the market on Monday, August 8, 2022.
The company’s management will host a conference call and webcast to discuss its financial results at 4:30 p.m. ET on the same day.
Conference call and webcast details
A live webcast of the conference can be accessed here: or via the webcast link on the Company’s Investor Relations page web site, https://ir.castlebiosciences.com/overview/default.aspx. Please access the webcast at least 10 minutes prior to the start time of the conference call. An archive of the webcast will be available on the company’s website until August 31, 2022.
To access the live conference call by telephone, dial 1 844 200 6205 from the United States or +1 929 526 1599 internationally, at least 10 minutes prior to the start of the call, using conference ID 705869.
There will be a short question and answer session following the management’s remarks.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company that improves health through innovative tests that guide patient care. The company aims to transform disease management by putting people first: patients, doctors, employees and investors.
Castle’s current portfolio consists of tests for skin cancer, uveal melanoma, Barrett’s esophagus and mental health conditions. In addition, the company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict response to systemic therapy in patients with moderate to severe psoriasis, atopic dermatitis and conditions related For more information, visit www.CastleBiosciences.com and connect with us LinkedIn, Facebook, Twitter i Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.